Want to join the conversation?
Drug and medical device maker $BAX reported a jump in 2Q16 earnings driven by a $1.1Bil realized gains on the disposition of its retained shares in Baxalta. Net income rose to $1.21Bil or $2.19 per share from $332MM or $0.60 per share last year. Net sales grew to $2.59Bil from $2.48Bil. Adjusted EPS increased to $0.46 from $0.19.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)